Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.51 |
| ▸ | JAK3 | P52333 | 11/20 | 0.51 |
| ▸ | GRK6 | P43250 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2161004 | 0.99 | JAK2 (0.50) | JAK2JAK3GRK6MAPTKCNH2 | |
| Hydrochloric Acid SCHEMBL1396518 | 0.99 | JAK2 (0.50) | JAK2JAK3GRK6MAPTKCNH2 | |
| SCHEMBL2161322 | 0.90 | JAK2 (0.53) | JAK2JAK3MAPT | |
| SCHEMBL1396349 | 0.90 | JAK2 (0.53) | JAK2JAK3MAPT | |
| SCHEMBL2160773 | 0.90 | JAK2 (0.53) | JAK2JAK3MAPT | |
| SCHEMBL2161224 | 0.88 | JAK2 (0.49) | JAK2JAK3GRK6 | |
| SCHEMBL1396078 | 0.84 | GRK6 (0.48) | JAK2JAK3GRK6 | |
| SCHEMBL2161185 | 0.84 | GRK6 (0.48) | JAK2JAK3GRK6 | |
| SCHEMBL2162006 | 0.82 | JAK2 (0.47) | JAK2JAK3 | |
| SCHEMBL13942616 | 0.81 | JAK3 (0.75) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | JAK2 6/4885JAK3 188/4885GRK6 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.